Abstract Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first
in a new class of drugs that combines neprilysin inhibition with angiotensin II receptor …

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …

Abstract Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular
sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin …

Hypertension (HTN) is a common disease state associated with extensive morbidity and
mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal …

Sacubitril/valsartan is a first-in-class dual action molecule of the neprilysin (NEP) inhibitor
sacubitril (AHU-377) and the angiotensin II (Ang II) type 1 (AT1) receptor blocker (ARB) …

Heart failure affects≈ 5.7 million people in the United States alone. Angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists …

LCZ696 (sacubitril/valsartan) is a first-in-class dual action molecule of the neprilysin inhibitor
sacubitril and the angiotensin II type 1 receptor blocker valsartan. This drug has been …

The combination of neprilysin inhibitor sacubitril with the angiotensin II receptor 1 blocker
valsartan is the first agent from the angiotensin receptor neprilysin inhibitors (ARNI) class …

Recent studies have proven benefit of SGLT2i drugs in patients with heart failure with
reduced ejection fraction (HFrEF), but their safety when combined with angiotensin …

Sacubitril/valsartan is a novel, first-in-class drug, which combines a neprilysin inhibitor with
an angiotensin receptor blocker. Sacubitril inhibits neprilysin endopeptidase, blocking the …